The stock of Bionano Genomics Inc. (NASDAQ:BNGO) last traded at $0.62, down -2.97% from the previous session.
Data from the available sources indicates that Bionano Genomics Inc. (NASDAQ:BNGO) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.50 and a low of $1.75, we find $3.00. Given the previous closing price of $0.64, this indicates a potential upside of 368.75 percent. BNGO stock price is now -8.06% away from the 50-day moving average and -55.78% away from the 200-day moving average. The market capitalization of the company currently stands at $193.06M.
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $3.68 as their price target over the next twelve months.
With the price target of $4, Scotiabank recently initiated with Sector Outperform rating for Bionano Genomics Inc. (NASDAQ: BNGO).
In other news, Mamuszka Hannah, Director bought 65,789 shares of the company’s stock on Jun 13. The stock was bought for $50,000 at an average price of $0.76. Upon completion of the transaction, the Director now directly owns 65,789 shares in the company, valued at $40789.18. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President and CEO Holmlin R. Erik bought 15,000 shares of the business’s stock. A total of $9,639 was incurred on buying the stock at an average price of $0.64. This leaves the insider owning 806,474 shares of the company worth $0.5 million. Insiders disposed of 111,637 shares of company stock worth roughly $69214.94 over the past 1 year. A total of 1.82% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BNGO stock. A new stake in Bionano Genomics Inc. shares was purchased by QUADRATURE CAPITAL LTD during the first quarter worth $107,000. SEI INVESTMENTS CO invested $24,000 in shares of BNGO during the first quarter. In the first quarter, IVC WEALTH ADVISORS LLC acquired a new stake in Bionano Genomics Inc. valued at approximately $18,000. CERTIFIED ADVISORY CORP acquired a new stake in BNGO for approximately $10,000. AIGEN INVESTMENT MANAGEMENT, LP purchased a new stake in BNGO valued at around $9,000 in the second quarter. In total, there are 212 active investors with 27.30% ownership of the company’s stock.
With an opening price of $0.6473 on Tuesday morning, Bionano Genomics Inc. (NASDAQ: BNGO) set off the trading day. During the past 12 months, Bionano Genomics Inc. has had a low of $0.55 and a high of $4.35. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 3.70, and a quick ratio of 2.90. The fifty day moving average price for BNGO is $0.6790 and a two-hundred day moving average price translates $1.4061 for the stock.
The latest earnings results from Bionano Genomics Inc. (NASDAQ: BNGO) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.11 by -0.01. This compares to -$0.11 EPS in the same period last year. The company reported revenue of $7.42 million for the quarter, compared to $5.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.18 percent. For the current quarter, analysts expect BNGO to generate $8.29M in revenue.
Bionano Genomics Inc.(BNGO) Company Profile
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
